Shanxi C&Y Pharmaceutical Group Co Ltd (300254) — Net Asset Quality Index
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Net Asset Quality Index of 32.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.59 Billion minus total liabilities of CN¥1.07 Billion yields net assets of CN¥514.07 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read how much debt does Shanxi C&Y Pharmaceutical Group Co Ltd carry for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanxi C&Y Pharmaceutical Group Co Ltd Net Asset Quality Index Over Time (2008–2025)
This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the index stands at 32.4%, representing net assets of CN¥514.07 Million against total assets of CN¥1.59 Billion CNY. For live market cap and overall valuation, see 300254 market cap overview.
Annual Net Asset Quality Index for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2025)
The table below presents the year-by-year Net Asset Quality Index for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Shanxi C&Y Pharmaceutical Group Co Ltd (300254) strategic asset index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 36.2% | CN¥594.33 Million | CN¥1.64 Billion | CN¥1.05 Billion | ▼ -2.5 pp |
| 2024 | 38.6% | CN¥598.18 Million | CN¥1.55 Billion | CN¥949.55 Million | ▼ -15.7 pp |
| 2023 | 54.3% | CN¥778.43 Million | CN¥1.43 Billion | CN¥654.64 Million | ▲ +8.3 pp |
| 2022 | 46.1% | CN¥729.68 Million | CN¥1.58 Billion | CN¥854.64 Million | ▼ -2.7 pp |
| 2021 | 48.8% | CN¥744.58 Million | CN¥1.53 Billion | CN¥782.23 Million | ▲ +0.3 pp |
| 2020 | 48.5% | CN¥872.61 Million | CN¥1.80 Billion | CN¥927.91 Million | ▼ -3.3 pp |
| 2019 | 51.8% | CN¥932.60 Million | CN¥1.80 Billion | CN¥869.43 Million | ▼ -10.5 pp |
| 2018 | 62.3% | CN¥931.24 Million | CN¥1.50 Billion | CN¥564.47 Million | ▼ -1.7 pp |
| 2017 | 64.0% | CN¥971.17 Million | CN¥1.52 Billion | CN¥547.42 Million | ▼ -2.7 pp |
| 2016 | 66.7% | CN¥954.85 Million | CN¥1.43 Billion | CN¥477.74 Million | ▼ 0.0 pp |
| 2015 | 66.7% | CN¥872.50 Million | CN¥1.31 Billion | CN¥435.93 Million | ▼ -3.0 pp |
| 2014 | 69.7% | CN¥823.16 Million | CN¥1.18 Billion | CN¥358.17 Million | ▼ -0.7 pp |
| 2013 | 70.4% | CN¥767.16 Million | CN¥1.09 Billion | CN¥323.21 Million | ▼ -8.4 pp |
| 2012 | 78.7% | CN¥651.17 Million | CN¥827.16 Million | CN¥175.99 Million | ▼ -4.0 pp |
| 2011 | 82.7% | CN¥581.17 Million | CN¥702.56 Million | CN¥121.39 Million | ▲ +29.5 pp |
| 2010 | 53.3% | CN¥149.59 Million | CN¥280.84 Million | CN¥131.25 Million | ▲ +7.9 pp |
| 2009 | 45.3% | CN¥117.60 Million | CN¥259.51 Million | CN¥141.91 Million | ▼ -2.3 pp |
| 2008 | 47.6% | CN¥106.70 Million | CN¥224.15 Million | CN¥117.45 Million | — |